Evidence map›Paper›PMID 35516257›Full record

ArticleRSC advances2020

Design, synthesis and bioevaluation of novel 6-substituted aminoindazole derivatives as anticancer agents.

Ngo Xuan Hoang, Van-Hai Hoang, Thi-Thu-Trang Luu, Hung N Luu, Thien Ngo, Duong Van Hieu, Nguyen Huu Long, Le Viet Anh, Son Tung Ngo, Yen Thi Kim Nguyen and 5 more

Abstract read
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ngo Xuan HoangHanoi University of Pharmacy 13-15 Le Thanh Tong Hanoi 100000 Vietnam thaotp119@gmail.com.
Van-Hai HoangLaboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University Seoul 08826 Republic of Korea.
Thi-Thu-Trang LuuCollege of Pharmacy, Natural Products Research Institute, Seoul National University Seoul 08826 Republic of Korea.
Hung N LuuDivision of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh Pittsburgh PA 15232 USA.ORCID https://orcid.org/0000-0002-2172-1849
Thien NgoFaculty of Pharmacy, Thai Binh University of Medicine and Pharmacy Thai Binh City 410000 Vietnam.
Duong Van HieuHanoi University of Pharmacy 13-15 Le Thanh Tong Hanoi 100000 Vietnam thaotp119@gmail.com.
Nguyen Huu LongHanoi University of Pharmacy 13-15 Le Thanh Tong Hanoi 100000 Vietnam thaotp119@gmail.com.
Le Viet AnhHanoi University of Pharmacy 13-15 Le Thanh Tong Hanoi 100000 Vietnam thaotp119@gmail.com.
Son Tung NgoLaboratory of Theoretical and Computational Biophysics, Ton Duc Thang University Ho Chi Minh City 700000 Vietnam.ORCID https://orcid.org/0000-0003-1034-1768
Yen Thi Kim NguyenCollege of Pharmacy, Seoul National University Seoul 08826 Republic of Korea.
Byung Woo HanCollege of Pharmacy, Seoul National University Seoul 08826 Republic of Korea.
Thanh Xuan NguyenDepartment of Surgical Oncology, Viet-Duc University Hospital Hanoi 100000 Vietnam.
Dinh Thi Thanh HaiHanoi University of Pharmacy 13-15 Le Thanh Tong Hanoi 100000 Vietnam thaotp119@gmail.com.
Tran Thi Thu HienVietnam University of Traditional Medicine 2 Tran Phu, Ha Dong Hanoi 100000 Vietnam.
Phuong-Thao TranHanoi University of Pharmacy 13-15 Le Thanh Tong Hanoi 100000 Vietnam thaotp119@gmail.com.ORCID https://orcid.org/0000-0003-4855-2544

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, a series of 6-substituted aminoindazole derivatives were designed, synthesized, and evaluated for bio-activities. The compounds were initially designed as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors based on the structural feature of five IDO1 inhibitors, which are currently on clinical trials, and the important anticancer activity of the indazole scaffold. One of them, compound

Identifiers

PMID35516257
PMCPMC9058813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.